FDA places clinical hold on Concert Pharma's hair loss drug

(Reuters) – Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) imposed a clinical hold on a trial testing the company’s drug to treat alopecia areata, a type of hair loss.


Source: Reuters Health News